Study of CPAP Treatment Effects on Polycythemia in Adults with Moderate to Severe Obstructive Sleep Apnea

What this Trial Is About

Researchers are evaluating the effect of continuous positive airway pressure CPAP treatment on polycythemia in patients with obstructive sleep apnea OSA. This randomized, parallel-group, nonblinded clinical trial compares patients receiving CPAP along with diet and standard pharmacological treatment to those receiving only diet and pharmacological treatment. The study focuses on changes in hematocrit levels over 12 months to understand how CPAP influences polycythemia in this patient group. Participants diagnosed with moderate to severe OSA and polycythemia will be randomly assigned to either a CPAP treatment group or a control group. The CPAP treatment involves using a nasal mask with pressure automatically adjusted by a device during sleep, combined with diet and medication. The control group receives diet and pharmacological treatment without CPAP. The treatment period lasts 12 months, with regular visits to check treatment adherence and collect data. During the study, participants will attend visits at 12, 24, and 52 weeks for assessments including blood tests measuring hematocrit, hemoglobin, coagulation, and other blood parameters. Questionnaires on sleepiness, quality of life, and physical activity will also be completed. Researchers will monitor changes in blood counts, oxygen levels during sleep, and quality of life measures to evaluate the impact of CPAP on polycythemia and related health factors.

CPAP Effect on the Polycythemia in Patients With Obstructive Sleep Apnea